Competition Bureau completes preliminary investigation concerning relabelled biologic drugs
Monday, June 27, 2022 @ 4:53 PM | By Daniel Escudero
The Competition Bureau has completed a preliminary investigation into potential anticompetitive harm from relabelled biologic drugs, and has closed that investigation because the drugs in question have not been marketed in...